|  |  |
| --- | --- |
|  | |
| Book Name: | [**Medical Science: Trends and Innovations**](https://www.bookpi.org/bookstore/product/medical-science-trends-and-innovations-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4357** |
| Title of the Manuscript: | **Macrohematuria in the Course of Rivaroxaban Therapy: A Case of Bladder Tumor** |
| Type of the Article | **Book Chapter** |

|  |  |  |
| --- | --- | --- |
| PART 1: Comments | | |
|  | Reviewer’s comment | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | **1.- Rivaroxaban is a relatively safe oral anticoagulant.**  **2.- Hemorrhagic side effects cannot be ruled out, as in this clinical case.**  **3. The clinical area must always keep in mind that hemorrhagic events can occur in any part of the body and the urorenal tract must be monitored.**  **4.- When we find a patient who is on oral anticoagulant therapy and presents hematuria, we should not be overconfident and it will be necessary to monitor and rule out other possibilities.** |  |
| **Is the title of the article suitable?**  **(If not please suggest an alternative title)** | **YES** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **YES** |  |
| **Is the manuscript scientifically, correct? Please write here.** | **YES** |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.**  **-** | **YES** |  |
| Is the language/English quality of the article suitable for scholarly communications? | YES |  |
| Optional/General comments | This clinical case is very interesting to me, since the health professionals considered doing a complete study and not attributing the hematuria exclusively to the use of rivaroxaban, which is the most common, and thanks to that expertise a diagnosis of malignancy was concluded.  This case seems illustrative to me to not take situations for granted and to always go beyond for the benefit of patients. |  |

|  |  |  |
| --- | --- | --- |
| **PART 2:** | | |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?** | *(If yes, Kindly please write down the ethical issues here in details)* |  |
| **Reviewer Details:** | | |
| Name: | **Martha Alvarado Ibarra** | |
| Department, University & Country | **Hospital Angeles Lomas, Mexico** | |